Impact of iron overload by transfusion on survival and leukemia transformation of myelodysplastic syndromes in a single center of China

Figures & data

Table 1. Demographic and characteristics of patients.

	All patients	IOL	NIOL
N (%)	143	37	106
Median age (range), years	56.8 (15–87)	52 (21–82)	61.5 (15–87)
Gender
Male	96	33	63
Female	47	4	43
RBC units transfusion	39.52 ± 62.89	67.80 ± 46.62 (14–288)	3.52 ± 8.04 (0–36)
Classification of WHO
RA	5	2	3
RN	4	0	4
RT	3	0	3
RARS	19	8	11
RCMD	33	12	21
RAEB-1	19	4	15
RAEB-2	30	9	21
MDS/MPN	2	0	2
5q-syndrome	3	0	3
Unclassified	25	3	22
IPSS
Low	13	3	10
Int-1	75	21	54
Int-2	42	9	33
High	13	4	9
WPSS
Very low	9	0	9
Low	29	6	23
Int	30	11	19
High	59	15	44
Very high	16	5	11
Leukemia transformation	19	5	14
Survival
Yes	51	8	43
No	59	19	40
Loss of follow-up	33	10	23

*IOL: iron overload; NIOL: non-iron overload.

Table 2. Level of intracellular ROS and iron in CD34+ cells of bone marrow.

	IOL group (N = 35)	NIOL group (N = 95)	p
ROS (ng/mL)	239.36 ± 77.10	143.87 ± 67.89	0.019
Iron (μmol/L)	0.020 ± 0.004	0.017 ± 0.001	0.043
SF (ng/mL)	1555 ± 253.9	351.5 ± 240.8	<0.001
LIC (μmol/L)	41.25 ± 12.75	31.10 ± 12.71	0.042

Table 3. Iron stain of bone marrow in MDS patients.

	- ∼ +	++	+++	++++	Total
IOL group (n)	12	8	11	4	35
NIOL group (n)	32	26	7	1	66

Figure 1. Influence of IOL on median survival time and LFS of MDS patients. A: A median survival time for MDS patients with IOL and NIOL (P = 0.040); B: The survival rate of LFS of MDS patients with IOL and NIOL (P = 0.037).

Table 4. Abnormality of chromosome of MDS.

	All patients (n) (%)	IOL patients (n) (%)	NIOL patients (n) (%)
Total	122	32 (25.6)	90 (74.4)
Normal	42 (34.4)	12 (37.5)	30 (33.3)
Abnormal	80 (65.6)	20 (62.5)	60 (66.7)
+8	34 (42.5)	8 (40.0)	26 (43.3)
–7/del(7q)	25 (31.3)	10 (50.0)	15 (25.0)
–Y	13 (16.3)	2 (10.0)	11 (18.3)
del(20q)	18 (22.5)	5 (25.0)	13 (21.7)
del(5q)	12 (15.0)	2 (10.0)	10 (16.7)
–5	3 (3.8)	2 (10.0)	1 (1.6)
≥3 abnormality	24 (30.0)	6 (30.0)	18 (30.0)